CHRDL1 and thyroid gland carcinoma: In BLCA (HR = 1.4, p = 0.038), and COAD (HR = 1.7, p = 0.039), RFS was lower in high-expression group of CHRDL1, and in adrenocortical carcinoma (ACC) (HR = 0.49, p = 0.041), SKCM (HR = 0.76, p = 0.025), and thyroid carcinoma (THCA) (HR = 0.4, p = 0.0028), RFS was lower in low-expression group of CHRDL1(Figure 3A; Supplementary Figure S1A, B).